NCT01786382已完成1 期
A Phase 1, Open-Label Study to Evaluate the Potential Effects of PPI-668 on the Pharmacokinetics of Midazolam and Omeprazole, and Potentially Telaprevir, in Healthy Adult Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Omeprazole maximum observed plasma concentration (Cmax)
研究概览
简要总结
The primary objectives of the study are to:
- Evaluate the potential effects of PPI-668 at steady state on the pharmacokinetic (PK) profile of midazolam following a single oral dose in human subjects.
- Evaluate the potential effects of PPI-668 at steady state on the PK profile of omeprazole following a single oral dose in human subject
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subject or legally authorized representative signs an Institutional Review Board (IRB)-approved written informed consent and privacy language as per national regulations (e.g., Health Insurance Portability and Accountability Act [HIPAA] authorization for sites in the United States) before any study-related procedures (including withdrawal of prohibited medication, if applicable) are performed
- •Age 18 to 50 years
- •Body mass index (BMI) 18-32 kg/m2
- •Clinical and laboratory findings consistent with good health in the opinion of the investigator
- •Women of non-childbearing potential or men who agree to utilize adequate contraception throughout the study
- •Women of non-childbearing potential must be one of the following:
- •Postmenopausal (>2 years amenorrhea and postmenopausal status confirmed by follicle-stimulating hormone levels)
- •Surgically sterile (documentation of prior tubal ligation, hysterectomy, or oophorectomy is required)
- •Male subjects who are not surgically sterile must agree to use one of the following birth control methods if sexually active:
- •Double-barrier contraceptive (e.g., condom plus diaphragm, condom or diaphragm with spermicidal gel/foam)
- •Female partner is at least two years postmenopausal or surgically sterile
排除标准
- •Positive results on any of the following tests at Screening or Day -1:
- •urine pregnancy (women only), urine drugs of abuse and alcohol, hepatitis B surface antigen, hepatitis C antibody, and human immunodeficiency virus antibody
- •Concurrent clinically significant medical diagnosis that would potentially interfere with the subject's study compliance or confound the study results
- •Concurrent social conditions (e.g., drug or alcohol abuse, transportation difficulties) that would potentially interfere with the subject's study compliance
- •Clinically significant illness within 30 days preceding entry into the study
- •Participation in an investigational drug study within 30 days or 5 half-lives, whichever is longer, before Screening
- •Use of prescription medications within 14 days before Day 1 and throughout the study. (The use of non-prescription or over-the-counter medications is prohibited within 7 days before Day 1 and throughout the study. This includes all herbal supplements or remedies and vitamins.)
研究组 & 干预措施
midazolam
Experimental
potential effects of PPI-668 on midazolam pharmacokinetics
干预措施: PPI-668 (Drug)
midazolam
Experimental
potential effects of PPI-668 on midazolam pharmacokinetics
干预措施: Midazolam (Drug)
omeprazole
Experimental
potential effects of PPI-668 on omeprazole pharmacokinetics
干预措施: PPI-668 (Drug)
omeprazole
Experimental
potential effects of PPI-668 on omeprazole pharmacokinetics
干预措施: Omeprazole (Drug)
telaprevir
Experimental
potential effects of PPI-668 on telaprevir pharmacokinetics
干预措施: PPI-668 (Drug)
telaprevir
Experimental
potential effects of PPI-668 on telaprevir pharmacokinetics
干预措施: Telaprevir (Drug)
结局指标
主要结局
Omeprazole maximum observed plasma concentration (Cmax)
时间窗: Days 1-6
Midazolam area under the plasma concentration-time curve from time 0 to 24 hours after dosing (AUC0-24)
时间窗: Days 1-6
Midazolam maximum observed plasma concentration (Cmax)
时间窗: Days 1-6
Omeprazole area under the plasma concentration-time curve from time 0 to 24 hours after dosing (AUC0-24)
时间窗: Days 1-6
次要结局
- Telaprevir area under the plasma concentration-time curve from time 0 to 24 hours after dosing (AUC0-24)(Days 1-12)
- Telaprevir maximum observed plasma concentration (Cmax)(Days 1-12)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise HealthyHealthy VolunteerNCT04839393Pfizer27
已完成
1 期
A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy ParticipantsHealthy VolunteerNCT06264440Biogen18
已完成
2 期
Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis CChronic Hepatitis CNCT01859962Presidio Pharmaceuticals, Inc.38
已完成
1 期
Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of NBI-98854 in Healthy SubjectsEffect of Ketoconazole on the PK of NBI-98854 in Healthy SubjectsNCT01910480Neurocrine Biosciences24
已完成
1 期
Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics of a Single 3 mg Cytisinicline DoseRenal ImpairmentNCT05631938Achieve Life Sciences44